16202-15-6

Usage

Uses

(S)-Tropic Acid is used as a reagent in the synthesis of Scopolamine (S200005) and its salts.

Upstream product

• 529-64-6 Tropic acid 
• 131682-38-7 (+)-3-acetoxy-2-phenylpropionic acid 
• 17659-49-3 (-)-Anisodamine 
• 126371-43-5 7b-Hydroxyhyoscyamine 
• 7647-01-0 hydrogenchloride 
• 51-34-3 scopolamine 
• 10035-10-6 hydrogen bromide 
• 51545-26-7 3-chloro-2-phenyl-propionic acid 
• 135859-72-2 (S)-tropic acid lactone 
• 110230-69-8 (S)-1-acetoxy-3-hydroxy-2-phenylpropane 
• 98017-92-6 2-phenyl-1,3-propanediol diacetate 
• 131216-60-9 Acetic acid (R)-2-(2,4-dichloro-phenyl)-3-hydroxy-propyl ester 
• 110270-51-4 (R)-1-acetoxy-3-hydroxy-2-phenylpropane 
• 171432-99-8 (R)-2-phenyl-3-hydroxypropyl butyrate 

Downstream Products

• 101-31-5 Hyoscyamine 
• 37504-67-9 (αS)-α-(acetoxymethyl)benzeneacetic acid 
• 183626-74-6 (αS)-α-(acetoxymethyl)benzeneacetyl chloride 
• 92934-63-9 S-(-)-tropicamide 
• 177567-34-9 Acetic acid (S)-2-(ethyl-pyridin-4-ylmethyl-carbamoyl)-2-phenyl-ethyl ester 
• 65189-78-8 (-)-2-phenyl-2-carboxyethyl ester of 1-p-chlorobenzoyl-5-methoxy-2-methyl-3-indolylacetic acid 
• 65189-78-8 (+)-2-phenyl-2-carboxyethyl ester of 1-p-chlorobenzoyl-5-methoxy-2-methyl-3-indolylacetic acid 
• 126371-43-5 7b-Hydroxyhyoscyamine 

Relevant academic research and scientific papers

Analogs of sub-nanomolar hMC1R agonist LK-184 [Ph(CH2) 3CO-His-D-Phe-Arg-Trp-NH2]. An additional binding site within the human melanocortin receptor 1?

Twenty nine analogs of a superpotent MC1R agonist LK-184 (1) were tested at human melanocortin receptors (hMC1, hMC3, and hMC4Rs). All derivatives with the spacer between the N-terminus and the aromatic ring longer or shorter than C3 were much less potent at hMC1R than 1. Only LK-312 PhCO(CH 2)3CO-His-D-Phe-Arg-Trp-NH2 (3), partially mimicking the π-system of 1, had an EC50 of 0.05nM at hMC1R, which confirms the localization of the π-binding zone of the receptor. Truncation of 1 to Ph(CH2)3CO-His-D-Phe-Arg-NH2 gave a full MC1 agonist, LK-394 (30), with an EC50 of 5nM and a weak partial agonism at MC3/4Rs. This suggests the existence of an additional binding site within hMC1R next to that for the core sequence His-D-Phe-Arg-Trp-NH 2.

PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS

The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS

The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

Enantioseparation of typical pesticides using cellulose carbamate stationary phases by capillary liquid chromatography

Cellulose-tris(3,5-dimethylphenylcarbamate) was initially synthesized as the chiral selector, then stable coated and bonded chiral stationary phases were prepared, respectively, using aminopropyl-functionalized silica gel as the support media. The prepared stationary phases were used for micro-column chiral separation by self-installed capillary high performance liquid chromatography system. Eighteen kind of chiral compounds including some typical pesticides were tested on both prepared chiral stationary phases and different chromatographic parameters such as resolution and retention time were comparatively investigated.

High-performance liquid chromatography separation of enantiomers of mandelic acid and its analogs on a chiral stationary phase

The enantiomers of mandelic acid and its analogs have been chromatographically separated on a chiral stationary phase (CSP) derived from 4-(3,5-dinitrobenzamido) tetrahydrophenanthrene. The rationale of separations of these compounds is discussed with respect to the method development for determining enantiomeric purity and possibility of obtaining enantiomerically pure materials by high-pressure liquid chromatography. The relationship of analyte structure to the extent of enantiomeric separation has been examined and separation factors (a) are presented for various groups of structurally related compounds. Chiral recognition models have been suggested to account for the observed separations. These models provide mechanistic insights into the chiral recognition process.

Enantiopure tert-butyl(phenyl)phosphine oxide. Chirality-recognition ability and mechanism

When enantiopure tert-butyl(phenyl)phosphine oxide 1 was used as a resolving agent, it showed an acceptable to good chirality-recognition ability for several kinds of racemic carboxylic acids 2. A study on a chirality-recognition mechanism based on X-ray crystallographic analyses of the diastereomeric complexes of 2 with 1 revealed that the complex crystals consisted of helical columns and that 1 was not responsible for the formation of the helical column and occupied a void between the columns; although 1 interacted with 2 via a hydrogen bond to primarily form a pair with 2, the complex crystals were mainly stabilized by the accumulation of weak interactions, such as CH/π, π/π and CH...O interactions, between 1/1, 1/2 and 2/2.

MUSCARINIC RECEPTOR ANTAGONISTS

This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

Enzymatic kinetic resolution of tropic acid

A new strategy has been developed for the CAL-B catalysed kinetic resolution of tropic acid by which both enantiomers of tropic acid can be obtained in good enantiomeric excess. (R)-Tropic acid was synthesised with 90% ee and (S)-tropic acid butyl ester in 99% ee by the hydrolysis of tropic acid butyl ester. The other enantiomers were available through the enzymatically catalysed reaction of tropic acid lactone with butanol to give (S)-tropic acid lactone and (R)-tropic acid ester in >98% ee.

Differential analgesic activity of the enantiomers of atropine derivatives does not correlate with their muscarinic subtype selectivity

The enantiomers of several tropic and p-substituted tropic acid esters related to atropine obtained by esterification under non-racemizing conditions after resolution of the corresponding racemic acids [(+)- and (-)-18, (+)- and (-)-19] are reported. They were tested in vitro on muscarinic subtype receptors and in vivo for their analgesic activity on mice. As in the case of the lead compound, R-(+)-hyoscyamine, these substances show enantioselectivity in analgesic tests, the eutomers being the R-(+) or R-(+)-p-substituted tropic acid derivatives. However, this property, which is a consequence of increased central release of ACh, seems unrelated to muscarinic subtype selectivity insofar as the compounds are unable to discriminate muscarinic subtype receptors. A possible explanation of these results which does not involve subtype selectivity is proposed, based on the recently developed concept of inverse agonism.

A Chemoenzymatic Synthesis of Both Enantiomers of 2-Phenyl-3-hydroxypropylcarbamate, a Metabolite of Felbamate

PPL catalyzed desymmetrization of 2-phenyl-1,3-propanediol (3) was the key step in the chemoenzymatic synthesis of both enantiomers of 2-phenyl-3-hydroxypropylcarbamate (2).Unsuccessful attempts at enzyme catalyzed (PPL, Novo SP435) transcarbamoylation, aminolysis and ammonolysis are also described.